Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 22

CLEOPATRA:
Significant improvement in median
PFS and OS
HR 0.68
p = 0.0002
0
40
60
80
100
20
Overall Survival (%)
0
10
20
30
40
50
60
70
Time (months)
Ptz+T+D: 56.5 mo.
Pla+T+D: 40.8 mo.
D=15.7 mo.
HR=0.62
p<0.0001
0
10
20
30
40
Time (months)
0
40
60
80
100
20
Progression-free Survival (%)
Ptz+T+D: 18.5 mo.
Pla+T+D: 12.4 mo.
D=6.1 mo.
Baselga et al., NEJM 2012., Swain et al., NEJM, 2015.
1...,12,13,14,15,16,17,18,19,20,21 23,24,25,26,27,28,29,30,31,32,...47
Powered by FlippingBook